C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle

Circulation

Volumn 107, Issue 13, 2003, Pages 1783-1790

  Wang, Chao Hung ^a   Li, Shu Hong ^a   Weisel, Richard D ^a   Fedak, Paul W M ^a   Dumont, Aaron S ^b   Szmitko, Paul ^a   Li, Ren Ke ^a   Mickle, Donald A G ^a   Verma, Subodh ^a,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF VIRGINIA   (United States)

^c TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Angiotensin; Atherosclerosis; C reactive protein; Smooth muscle

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; C REACTIVE PROTEIN; COLLAGEN; ELASTIN; LOSARTAN; REACTIVE OXYGEN METABOLITE; RECOMBINANT C REACTIVE PROTEIN; UNCLASSIFIED DRUG;

ANGIOPLASTY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROSIS; BINDING SITE; CAROTID ARTERY INJURY; CELL CULTURE; CELL MIGRATION; CELL PROLIFERATION; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DISEASE MARKER; DRUG MECHANISM; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR BINDING; RECEPTOR DENSITY; RNA STABILITY; VASCULAR SMOOTH MUSCLE;

ANGIOPLASTY, BALLOON; ANIMALS; C-REACTIVE PROTEIN; CAROTID STENOSIS; CELL DIVISION; CELL MOVEMENT; CELLS, CULTURED; GENE EXPRESSION REGULATION; HUMANS; KINETICS; MALE; MUSCLE, SMOOTH, VASCULAR; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, ANGIOTENSIN; RNA, MESSENGER; UP-REGULATION;

EID: 0037426399     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000061916.95736.E5     Document Type: Article

References (38)

1. Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286: 327-334.
2. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA. 2001;285:2481-2485.
3. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation. 2001;103:1813-1818.
4. Blake GJ, Ridker PM. High sensitivity C-reactive protein for predicting cardiovascular disease: an inflammatory hypothesis. Eur Heart J. 2001; 22:349-352.
5. Rifai N, Ridker PM. Proposed cardiovascular risk assessment algorithm using high-sensitivity C-reactive protein and lipid screening. Clin Chem. 2001;47:28-30.
6. Albert MA, Ridker PM. The role of C-reactive protein in cardiovascular disease risk. Curr Cardiol Rep. 1999;1:99-104.
7. Ridker PM. Are statins anti-inflammatory? Issues in the design and conduct of the pravastatin inflammation C-reactive protein evaluation. Curr Cardiol Rep. 2000;2:269-273.
8. Ridker PM, Rifai N, Stampfer MJ, et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000;101:1767-1772.
9. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-843.
10. Morrow DA, Ridker PM. C-reactive protein, inflammation, and coronary risk. Med Clin North Am. 2000;84:149-161.
11. Ridker PM. Novel risk factors and markers for coronary disease. Adv Intern Med. 2000;45:391-418.
12. Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem. 1999;45:2136-2141.
13. Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. Circ Res. 2001;89:763-771.
14. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135-1143.
15. Rifai N, Ridker PM. Inflammatory markers and coronary heart disease. Curr Opin Lipidol. 2002;13:383-389.
16. Blake GJ, Ridker PM, Kuntz KM. Projected life-expectancy gains with statin therapy for individuals with elevated C-reactive protein levels. J Am Coll Cardiol. 2002;40:49-55.
17. Blake GJ, Ridker PM. C-reactive protein and prognosis after percutaneous coronary intervention. Eur Heart J. 2002;23:923-925.
18. Albert CM, Ma J, Rifai N, et al. Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation. 2002;105:2595-2599.
19. Ridker PM. Inflammatory biomarkers, statins, and the risk of stroke: cracking a clinical conundrum. Circulation. 2002;105:2583-2585.
20. Kinlay S, Timms T, Clark M, et al. Comparison of effect of intensive lipid lowering with atorvastatin to less intensive lowering with lovastatin on C-reactive protein in patients with stable angina pectoris and inducible myocardial ischemia. Am J Cardiol. 2002;89:1205-1207.
21. Ridker PM. Should statin therapy be considered for patients with elevated C-reactive protein? The need for a definitive clinical trial. Eur Heart J. 2001;22:2135-2137.
22. Blake GJ, Ridker PM. Tumour necrosis factor-alpha, inflammatory biomarkers, and atherogenesis. Eur Heart J. 2002;23:345-347.
23. Albert MA, Danielson E, Rifai N, et al. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001;286:64-70.
24. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557-1565.
25. Zwaka TP, Hombach V, Torzewski J, C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation. 2001;103:1194-1197.
26. Pasceri V, Chang J, Willerson JT, et al. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation. 2001;103:2531-2534.
27. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000;102:2165-2168.
28. Yeh ET, Anderson HV, Pasceri V, et al. C-reactive protein: linking inflammation to cardiovascular complications. Circulation. 2001;104:974-975.
29. Verma S, Li SH, Badiwala MV, et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation. 2002;105:1890-1896.
30. Verma S, Wang CH, Li SH, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation. 2002;106:913-919.
31. Bendeck MP, Conte M, Zhang M, et al. Doxycycline modulates smooth muscle cell growth, migration, and matrix remodeling after arterial injury. Am J Pathol. 2002;160:1089-1095.
32. Macdonald RL, Zhang J, Weir B, et al. Adenosine triphosphate causes vasospasm of the rat femoral artery. Neurosurgery. 1998;42:825-832.
33. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-874.
34. Libby P, Aikawa M. Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat Med. 2002;8:1257-1262.
35. Bhatt DL, Topol EJ. Need to test the arterial inflammation hypothesis. Circulation. 2002;106:136-140.
36. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145-153.
37. 1-type angiotensin receptor in oxidative stress and atherogenesis: part I: oxidative stress and atherogenesis. Circulation. 2002;105:393-396.
38. Griselli M, Herbert J, Hutchínson WL, et al. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med. 1999;190:1733-1740.